- LEVITY
- Posts
- #9 From obscurity to spotlight: why this lifespan study has everybody excited
#9 From obscurity to spotlight: why this lifespan study has everybody excited
But is it more potent than rapamycin? Let's hear from the experts!
Peter Ottsjö
July 31, 2024
✅ What is IL-11 and why is everyone talking about it? ✅ They want to target ”the hardest hallmark in aging”. ✅ Longevity gets its day in parliament. ✅ Will longevity drugs only be for the rich? ✅ A new full length documentary on how to never die. ✅ Insights from Episode 4 of the LEVITY Podcast.
🤙🏼 Want to connect? Add me on LinkedIn. 🙏🏼 Not subscribed to the LEVITY podcast on Youtube yet? Do it here. 🎧 More of a listener? The LEVITY podcast is also available on Spotify, Apple Podcasts and other places.
”This should translate to humans” says author of paper that shows remarkable effects in aged mice
At AARD in 2022, a prominent aging conference held in Copenhagen every year, professor Stuart Cook hade been given a ten minute only slot. There were many empty seats as he rapidly navigated through his presentation and slides. In hindsight, what he showed was quite remarkable.
But if few paid attention then, everybody’s listening now. In longevity circles everybody is all of a sudden talking about Interleukin-11 (more commonly called IL-11), an inflammation boosting protein. Even major mainstream media outlets are covering it, which until recently was relatively obscure.
”Yes, the media attention has been quite amazing”, Stuart Cook tells me over e-mail.
